- Esperion Therapeutics recently reported their Q4 and full-year 2021 earnings. NEXLETOL and NEXLIZET together secured $12.2M in U.S. net product revenue, which is up 200% for the year.
- The company revealed improved commercial metrics including that scripts increased 9% over Q3 and that roughly 70K patients have filled their NEXLETOL or NEXLIZET scripts since launch.
- Esperion has bolstered their finances with a $209M financing. The company should have an ample capital to get past the CLEAR Outcomes topline data expected in Q1 of 2023.
- I provide my opinion on the company’s earnings and will discuss why I am narrowing my focus to the CLEAR Outcome topline data readout.
- I reveal my plans to take advantage of the discounted share price throughout 2022.
For further details see:
Esperion Therapeutics: Ready For Growth Ahead Of Clear Outcomes Topline Data Readout